The Oral Steroid and the Scope Question
A 38-year-old patient presents with a severe, unilateral, painful red eye following a chemical splash two days earlier. Best-corrected acuity is 20/60 in the affected eye. Slit-lamp examination shows diffuse punctate epithelial loss, a hazy view of the anterior chamber, and marked conjunctival injection. Dr. Brooks, who holds full therapeutic certification, wants to start intensive topical steroid and antibiotic drops and also considers a short course of oral prednisone to control inflammation. Dr. Brooks has not previously prescribed oral steroids and is unsure whether Arizona's optometric scope permits it. The patient is systemically healthy and takes no medications. Dr. Brooks also considers comanaging with an ophthalmologist but worries that transfer will delay care.
1. Analyze whether oral corticosteroid prescribing falls within Arizona optometric therapeutic authority, and how Dr. Brooks should proceed if uncertain.
Read the worked answer
Therapeutic certification in Arizona expands optometric practice to include pharmaceutical agents for ocular conditions, but the precise boundaries of systemic prescribing must be checked against the statute and Board rules rather than assumed. Oral corticosteroids for an ocular inflammatory condition sit at the edge of that authority, and Dr. Brooks should not prescribe outside a clearly established scope. The prudent course is to confirm the current statutory and rule language, and if oral steroids are not clearly authorized, to use topical therapy within scope and arrange ophthalmologic comanagement for the systemic component. Uncertainty about scope is resolved by consulting the governing law and the Board, not by proceeding and hoping the prescription is covered.
2. Given the chemical injury and hazy anterior chamber view, what clinical and comanagement considerations should drive the plan?
Read the worked answer
A chemical splash with reduced acuity, diffuse epithelial loss, and a hazy view raises concern for significant anterior segment injury, possible limbal ischemia, and intraocular involvement that may exceed what can be safely managed in an optometric setting alone. Dr. Brooks should ensure adequate irrigation and topical management within scope, but the hazy view and mechanism warrant urgent ophthalmologic evaluation. Comanagement is not a delay tactic; it is the appropriate escalation when the clinical picture suggests a condition at or beyond the edge of safe optometric management. The record should document the mechanism, findings, initial treatment, and the timing and rationale for referral.